loading
Sagimet Biosciences Inc stock is traded at $4.52, with a volume of 259.10K. It is up +2.49% in the last 24 hours and down -16.45% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
See More
Previous Close:
$4.41
Open:
$4.41
24h Volume:
259.10K
Relative Volume:
0.18
Market Cap:
$144.88M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-3.9192
EPS:
-1.1533
Net Cash Flow:
$-22.80M
1W Performance:
-24.92%
1M Performance:
-16.45%
6M Performance:
-4.64%
1Y Performance:
+50.17%
1-Day Range:
Value
$4.27
$4.5475
1-Week Range:
Value
$4.19
$5.96
52-Week Range:
Value
$2.39
$20.71

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name
Name
Sagimet Biosciences Inc
Name
Phone
(650) 561-8600
Name
Address
155 BOVET RD., SUITE 303, SAN MATEO
Name
Employee
10
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SGMT's Discussions on Twitter

Compare SGMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
SGMT 4.52 144.88M 0 -29.25M -22.80M -1.1533
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Sagimet Biosciences Inc Stock (SGMT) Latest News

pulisher
Nov 19, 2024

Sagimet Biosciences participates ik,on No - TipRanks

Nov 19, 2024
pulisher
Nov 19, 2024

HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences keeps stock target with Buy rating on phase 3 program - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor da - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLDThe Liver Meeting® 2024 - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Sagimet's Denifanstat Shows 49% Fibrosis Improvement in Phase 2b MASH Trial | SGMT Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance

Nov 18, 2024
pulisher
Nov 16, 2024

Sagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Steven Cohen's Strategic Acquisition in Sagimet Biosciences Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Hillhouse Capital Management's Strategic Reduction in Sagimet Bi - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Baker Bros. Advisors LP Increases Stake in Sagimet Biosciences I - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $24.00 Consensus Price Target from Analysts - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Advances MASH Treatment with Denifanstat - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet: More Than Just A MASH Drug Development Biotech (NASDAQ:SGMT) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences reports Q3 EPS (45c) vs (35c) last year - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Sagimet Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 13, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 Once-Daily Oral Tablet for Treatment of Acne - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

UBS says Sagimet stock could steal the MASH spotlight from injectables - Investing.com Canada

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet stock draws buy at UBS on MASH(SGMT:NASDAQ) - Seeking Alpha

Nov 12, 2024
pulisher
Nov 12, 2024

SGMTSagimet Biosciences Inc. Series A Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Price Target at $24.00 - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS Group - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

Sagimet Biosciences initiated with a Buy at UBS - TipRanks

Nov 12, 2024
pulisher
Nov 10, 2024

Sagimet Biosciences Insiders Benefit From Selling Stock At US$3.10 - Simply Wall St

Nov 10, 2024
pulisher
Nov 08, 2024

Trend Tracker for (SGMT) - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 07, 2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference - The Manila Times

Nov 07, 2024
pulisher
Nov 04, 2024

Sagimet planning Phase 3 trials of denifanstat in MASH, MASLD - Liver Disease News

Nov 04, 2024
pulisher
Oct 31, 2024

HC Wainwright Reaffirms "Buy" Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Sagimet’s denifanstat enters Phase III trials for MASH treatment - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-Of-Phase 2 Interactions with Fda on the Development of Denifanstat for Mash - Marketscreener.com

Oct 29, 2024
pulisher
Oct 29, 2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

(SGMT) Technical Data - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 26, 2024

Sagimet Biosciences Inc. (NASDAQ:SGMT) Short Interest Update - MarketBeat

Oct 26, 2024
pulisher
Oct 18, 2024

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha

Oct 18, 2024
pulisher
Oct 18, 2024

(SGMT) Investment Analysis and Advice - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 16, 2024

There is no way Sagimet Biosciences Inc (SGMT) can keep these numbers up - SETE News

Oct 16, 2024
pulisher
Oct 16, 2024

Market Highlights: Sagimet Biosciences Inc (SGMT) Ends on a Low Note at 5.13 - The Dwinnex

Oct 16, 2024
pulisher
Oct 16, 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLDThe Liver Meeting® 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

How to interpret Sagimet Biosciences Inc (SGMT)’s stock chart patterns - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Sagimet Biosciences Inc’s Shares Reel: 42.19% Quarterly Revenue Decline Amid 167.12M Market Cap - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

SGMT (Sagimet Biosciences Inc) may reap gains as insiders became active recently - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in the Lancet Gastroenterology and Hepatology - Marketscreener.com

Oct 14, 2024
pulisher
Oct 11, 2024

Sagimet Gains on Latest Numbers - Baystreet.ca

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet's denifanstat shows promise in Phase 2b MASH trial By Investing.com - Investing.com UK

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial - The Bakersfield Californian

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from - GlobeNewswire

Oct 11, 2024
pulisher
Oct 11, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - StockTitan

Oct 11, 2024

Sagimet Biosciences Inc Stock (SGMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Sagimet Biosciences Inc Stock (SGMT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Martins Eduardo Bruno
Chief Medical Officer
Jul 19 '24
Sale
3.10
8,357
25,910
81,213
Rozek Elizabeth
General Counsel and CCO
Jul 19 '24
Sale
3.10
10,914
33,830
160,506
Kemble George
Executive Chairman
Jul 19 '24
Sale
3.10
14,062
43,605
142,318
Happel David
President & CEO
Mar 26 '24
Buy
5.27
12,100
63,731
639,200
Happel David
President & CEO
Dec 07 '23
Buy
4.10
1,600
6,560
627,100
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):